Artículo
Gueron, G.; Avanzo, R.E.; Schuster, F.; Carabelos, M.N.; Vazquez, E.; Fascio, M.L.; D'Accorso, N.B. "Differential effect of heterocyclic d-ribofuranoside derivatives on human prostate cancer cell viability and cell cycle progression" (2014) Biomedicine and Pharmacotherapy. 68(7):847-854
Estamos trabajando para incorporar este artículo al repositorio
Consulte la política de Acceso Abierto del editor
Abstract:
New d-ribofuranoside derivatives containing two five membered heterocycles, isoxazole and triazole or two triazole rings, were synthesized. The final products as well as the synthetic precursors were physically and spectroscopically characterized. These new diheterocyclic derivatives together with other d-riboside compounds were assessed for their impact on PC3 cell line viability. We found that exposure of prostate cancer cells to some of these compounds caused a significant inhibition of cell growth and a G0/G1 cell cycle arrest, which was concomitant with alterations in the expression of proteins involved in cell cycle progression. Furthermore, the inhibitory activity was improved in di-heterocycles when the carbohydrate moiety was protected with a cyclopentylidene group compared to the isopropylidene analogues. © 2014 Elsevier Masson SAS.
Registro:
| Documento: | Artículo |
| Título: | Differential effect of heterocyclic d-ribofuranoside derivatives on human prostate cancer cell viability and cell cycle progression |
| Autor: | Gueron, G.; Avanzo, R.E.; Schuster, F.; Carabelos, M.N.; Vazquez, E.; Fascio, M.L.; D'Accorso, N.B. |
| Filiación: | CIHIDECAR-CONICET, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, Buenos Aires, CP C1428EGA, Argentina IQUIBICEN-CONICET, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón 2, Buenos Aires, CP C1428EGA, Argentina |
| Palabras clave: | D-Ribose; Isoxazole; PC3 cell line; Prostate cancer; Triazole; 2,3 o cyclopentylidene 5 tosyl beta dextro ribofuranoside; 2,3 o cyclopentylidene beta dextro ribofuranoside; 2,3 o isopropylidene 5 tosyl beta dextro ribofuranoside; 2,3 o isopropylidene beta dextro ribofuranoside; antineoplastic agent; isoxazole derivative; ribose; triazole derivative; unclassified drug; [1" (3,4,5 trimethoxyphenyl) triazol 4" yl]methyl 2,3 o cyclopentylidene 5 tosyl beta dextro ribofuranoside; [1" (3,4,5 trimethoxyphenyl) triazol 4" yl]methyl 2,3 o isopropylidene 5 tosyl beta dextro ribofuranoside; [1" (3,4,5 trimethoxyphenyl) triazol 4" yl]methyl 5 deoxy 5 (1,2,4, triazol 3 yl) 2,3 o cyclopentylidene beta dextro ribofuranoside; [1" (3,4,5 trimethoxyphenyl) triazol 4" yl]methyl 5 deoxy 5 (1,2,4, triazol 3 yl) 2,3 o isopropylidene beta dextro ribofuranoside; [3" (3,4,5 trimethoxyphenyl) isoxazol 5" yl]methyl 2,3 o cyclopentylidene 5 tosyl beta dextro ribofuranoside; [3" (3,4,5 trimethoxyphenyl) isoxazol 5" yl]methyl 2,3 o isopropylidene 5 tosyl beta dextro ribofuranoside; [3" (3,4,5 trimethoxyphenyl) isoxazol 5" yl]methyl 5 deoxy 5 (1,2,4, triazol 3 yl) 2,3 o cyclopentylidene beta dextro ribofuranoside; [3" (3,4,5 trimethoxyphenyl) isoxazol 5" yl]methyl 5 deoxy 5 (1,2,4, triazol 3 yl) 2,3 o isopropylidene beta dextro ribofuranoside; alkene; antineoplastic agent; carbohydrate; isoxazole derivative; propylene; triazole derivative; apoptosis; Article; cancer cell; cancer growth; carbohydrate analysis; carbon nuclear magnetic resonance; cell cycle progression; cell viability; controlled study; drug synthesis; G1 phase cell cycle checkpoint; G2 phase cell cycle checkpoint; heteronuclear multiple bond correlation; heteronuclear single quantum coherence; human; human cell; IC50; polyacrylamide gel electrophoresis; prostate cancer; prostate cancer cell line; protein expression; cell cycle G0 phase; cell survival; drug effects; male; Prostatic Neoplasms; tumor cell line; Alkenes; Antineoplastic Agents; Carbohydrates; Cell Line, Tumor; Cell Survival; G0 Phase; G1 Phase Cell Cycle Checkpoints; Humans; Isoxazoles; Male; Prostatic Neoplasms; Triazoles |
| Año: | 2014 |
| Volumen: | 68 |
| Número: | 7 |
| Página de inicio: | 847 |
| Página de fin: | 854 |
| DOI: | http://dx.doi.org/10.1016/j.biopha.2014.08.010 |
| Título revista: | Biomedicine and Pharmacotherapy |
| Título revista abreviado: | Biomed. Pharmacother. |
| ISSN: | 07533322 |
| CODEN: | BIPHE |
| CAS: | ribose, 34466-20-1, 50-69-1, 93781-19-2; propylene, 115-07-1; Alkenes; Antineoplastic Agents; Carbohydrates; Isoxazoles; propylene; Triazoles |
| Registro: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_07533322_v68_n7_p847_Gueron |
Referencias:
- Avanzo, R.E., Anesini, C., Fascio, M.L., Errea, M.I., D'Accorso, N.B., 1,2,4-Triazole D-ribose derivatives: design, synthesis and antitumoral evaluation (2012) Eur J Med Chem, 47, pp. 104-110
- Da Silva, E.N., Cavalcanti, B.C., Guimarães, T.T., Pinto, M.C.F.R., Cabral, I.O., Pessoa, C., Synthesis and evaluation of quinonoid compounds against tumor cell lines (2011) Eur J Med Chem, 46, pp. 399-410
- Akselsen, O.W., Odlo, K., Cheng, J.-J., Maccari, G., Botta, M., Hansen, T.V., Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1 (2012) Bioorg Med Chem, 20, pp. 234-242
- Beale, T.M., Bond, P.J., Brenton, J.D., Charnock-Jones, D.S., Ley, S.V., Myers, R.M., Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1 (2012) Bioorg Med Chem, 20, pp. 1749-1759
- Debicki, S., Jagodzinski, P.P., Apicidin decreases phospholipase C gamma-1 transcript and protein in Hut-78 T lymphoma cells (2009) Biomed Pharmacother, 63, pp. 543-547
- Łuczak, M.W., Jagodziński, P.P., Trichostatin A downregulates CYP19 transcript and protein levels in MCF-7 breast cancer cells (2009) Biomed Pharmacother, 63, pp. 262-266
- Khan, O., La Thangue, N.B., HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications (2012) Immunol Cell Biol, 90, pp. 85-94
- Patra, N., De, U., Kim, T.H., Lee, Y.J., Ahn, M.Y., Kim, N.D., A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via upregulation of androgen receptor expression in human prostate cancer cells (2013) Biomed Pharmacother, 67, pp. 407-415
- Chen, P.C., Patil, V., Guerrant, W., Green, P., Oyelere, A.K., Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group (2008) Bioorg Med Chem, 16, pp. 4839-4853
- Baulac, M., Introduction to zonisamide (2006) Epilepsy Res, 68 S, pp. S3-S9
- Chavez, M.L., DeKorte, C.J., Valdecoxib: A Review (2003) Clin Ther, 25, pp. 817-851
- Smolen, J.S., Kalden, J.R., Scott, D.L., Rozman, B., Kvien, T.K., Larsen, A., Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial (1999) Lancet, 353, pp. 259-266
- Selvam, C., Jachak, S.M., Thilagavathi, R., Chakraborti, K., Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents (2005) Bioorg Med Chem Lett, 15, pp. 1793-1797
- Simoni, D., Rizzi, M., Rondanin, R., Baruchello, R., Marchetti, P., Invidiata, F.P., Antitumor effects of curcumin and structurally β-diketone modified analogs on multidrug resistant cancer cells (2008) Bioorg Med Chem Lett, 18, pp. 845-849
- Sharp, S.Y., Prodromou, C., Boxall, K., Powers, M.V., Holmes, J.L., Box, G., Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues (2007) Mol Cancer Ther, 6, pp. 1198-1211
- Hahn, J.-S., The Hsp90 chaperone machinery: from structure to drug development (2009) BMB Rep, 42, pp. 623-630
- Chen, Y., Sawyers, C.L., Scher, H.I., Targeting the androgen receptor pathway in prostate cancer (2008) Curr Opin Pharmacol, 8, pp. 440-448
- Busscher, G.F., van den Broek, S.A.M.W., Rutjes, F.P.J.T., van Delft, F.L., Carbohydrate mimic of 2-deoxystreptamine for the preparation of conformationally constrained aminoglycosides (2007) Tetrahedron, 63, pp. 3183-3188
- Fascio, M.L., Montesano, V.J., D'Accorso, N.B., Synthesis and characterization of some 3-glycosyl-5-substituted isoxazolines with potential biological activities (2000) J Carbohydr Chem, 19, pp. 393-398
- Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation (2011) Cell, 144, pp. 646-674
Citas:
---------- APA ----------
Gueron, G., Avanzo, R.E., Schuster, F., Carabelos, M.N., Vazquez, E., Fascio, M.L. & D'Accorso, N.B. (2014) . Differential effect of heterocyclic d-ribofuranoside derivatives on human prostate cancer cell viability and cell cycle progression. Biomedicine and Pharmacotherapy, 68(7), 847-854.http://dx.doi.org/10.1016/j.biopha.2014.08.010
---------- CHICAGO ----------
Gueron, G., Avanzo, R.E., Schuster, F., Carabelos, M.N., Vazquez, E., Fascio, M.L., et al. "Differential effect of heterocyclic d-ribofuranoside derivatives on human prostate cancer cell viability and cell cycle progression" . Biomedicine and Pharmacotherapy 68, no. 7 (2014) : 847-854.http://dx.doi.org/10.1016/j.biopha.2014.08.010
---------- MLA ----------
Gueron, G., Avanzo, R.E., Schuster, F., Carabelos, M.N., Vazquez, E., Fascio, M.L., et al. "Differential effect of heterocyclic d-ribofuranoside derivatives on human prostate cancer cell viability and cell cycle progression" . Biomedicine and Pharmacotherapy, vol. 68, no. 7, 2014, pp. 847-854.http://dx.doi.org/10.1016/j.biopha.2014.08.010
---------- VANCOUVER ----------
Gueron, G., Avanzo, R.E., Schuster, F., Carabelos, M.N., Vazquez, E., Fascio, M.L., et al. Differential effect of heterocyclic d-ribofuranoside derivatives on human prostate cancer cell viability and cell cycle progression. Biomed. Pharmacother. 2014;68(7):847-854.http://dx.doi.org/10.1016/j.biopha.2014.08.010
